Agios Pharmaceuticals, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. The quarter marks a major strategic transition: Agios completed the sale of its oncology business to Servier on March 31 and is now focused on genetically defined diseases (GDDs). Oncology results are presented as discontinued operations, with prior-period results recast for comparability.
Key financial results
| Metric | Q1 2021 | Q1 2020 | Change / context |
|---|---|---|---|
| Continuing-operations revenue | No revenue reported | No revenue reported | Continuing operations reported research and development-stage losses. |
| Research and development expense | $57.7 million | $55.4 million | Increased $2.3 million, primarily from mitapivat trial start-up costs. |
| Selling, general and administrative expense | $33.6 million | $31.7 million | Increased $1.9 million, primarily due to ex-U.S. workforce-related costs. |
| Total operating expenses / operating loss | $91.2 million | $87.0 million | Expenses rose $4.2 million; operating loss equaled total expenses. |
| Interest income, net | $0.3 million | $2.9 million | Lower interest rates and a lower marketable-securities balance. |
| Continuing-operations net loss | $90.9 million | $84.1 million | Loss widened by $6.8 million. |
| Discontinued-operations net income | $1,965.2 million | $43.8 million | Primarily reflects the oncology-business sale gain. |
| Consolidated net income (loss) | $1,874.3 million | $(40.3) million | Q1 2021 result was dominated by the sale; it is not representative of recurring operating performance. |
| Operating cash flow | $(120.7) million | $(105.4) million | Continuing operations used $90.2 million, versus $78.8 million. |
| Cash, cash equivalents and marketable securities | $2,357.2 million | $670.5 million at Dec. 31, 2020 | Includes sale proceeds; balance-sheet cash was $1,888.0 million and marketable securities were $469.2 million. |
Margins: Not meaningful for continuing operations because no continuing revenue was reported. The oncology business reported discontinued-operations revenue of $41.4 million, down from $87.1 million in Q1 2020; its pre-tax operating loss before sale-related items was $8.8 million, compared with income of $43.8 million.
Sale accounting: Servier paid approximately $1.8 billion in cash at closing. Agios recorded a $1,992.6 million pre-tax gain and a $1,979.7 million after-tax gain on sale. Discontinued operations’ net income was $1,965.2 million after including operating results, non-cash interest expense and tax.
Debt and liquidity: The filing reports no conventional borrowing balance. At March 31, liabilities included $103.0 million of operating lease liabilities and $0.6 million of financing lease liabilities. Management said liquidity was sufficient for at least the next 12 months and expected existing resources, anticipated interest, future product sales and TIBSOVO royalties to fund operations through major catalysts and to cash-flow positivity without additional equity, excluding transaction-specific milestone payments.
Material changes and strategic developments
- Agios sold its oncology business—including TIBSOVO, vorasidenib, AG-270, AG-636 and oncology research programs—to Servier. Servier also acquired Agios’s IDHIFA co-commercialization rights and certain related rights.
- Agios retained contingent consideration: a potential $200 million payment if specified FDA approval conditions for vorasidenib are met before January 1, 2027; royalties of 5% on U.S. TIBSOVO net sales and 15% on U.S. vorasidenib net sales, subject to the agreement’s terms. These amounts are uncertain and were not recognized as income.
- The board authorized up to $1.2 billion of share repurchases. After quarter-end, Agios completed a $344.5 million repurchase of 7,121,658 shares from BMS affiliates on April 5, 2021, and established a Rule 10b5-1 plan permitting up to $600 million of additional repurchases.
- Cash provided by investing activities was $1,874.1 million, largely reflecting the sale proceeds; cash and cash equivalents increased by $1,760.6 million during the quarter.
Outlook, management commentary and risks
- Pipeline: Mitapivat is the lead GDD candidate for pyruvate kinase deficiency, thalassemia and sickle cell disease. Agios reported that the pivotal ACTIVATE and ACTIVATE-T trials met their primary endpoints. It expected to initiate the ENERGIZE and ENERGIZE-T phase 3 thalassemia trials in the second half of 2021 and a phase 2/3 sickle cell disease trial by year-end 2021.
- Regulatory plans: Agios anticipated filing for U.S. approval of mitapivat for adults with pyruvate kinase deficiency in Q2 2021 and filing in the EU in mid-2021, with potential launches in 2022 if approved. These were forward-looking expectations, not assured outcomes.
- Spending and profitability: Management expected significant continuing expenses and net losses while advancing GDD research, clinical development and potential commercialization. R&D expenses were expected to increase as programs advanced; SG&A was also expected to rise to support development and commercialization.
- COVID-19: Agios reported no significant direct financial or supply-chain impact as of March 31, 2021, but noted clinical-operation and enrollment disruptions at some sites. Further effects on trials, operations and financial results remained uncertain.
- Key risks: Clinical, regulatory and commercialization outcomes for mitapivat and other candidates; trial enrollment and COVID-related delays; dependence on third-party manufacturers and research organizations; competition and intellectual-property protection; and uncertainty over Servier milestone and royalty receipts. The sale also leaves Agios smaller and less diversified, and the planned repurchases reduce cash available for other uses.
- Controls: Management concluded disclosure controls were effective at the reasonable-assurance level. The sale led to changes in internal accounting controls for discontinued operations and related disclosures.
Investor verification priorities
- Confirm the sale’s final cash proceeds, adjustments and transaction costs, and distinguish the one-time gain from recurring results.
- Track mitapivat regulatory filings, trial timelines and outcomes, and the assumptions behind expected launch timing and cash-flow positivity.
- Monitor actual share repurchases, remaining authorization and their effect on cash, share count and capital allocation.
- Assess the terms, timing and likelihood of Servier’s vorasidenib milestone and product royalties; these are contingent, not committed cash receipts.
- Reconcile continuing-operations cash burn and expense trends against management’s liquidity runway expectations, including any effects from COVID-19 or clinical delays.